Jia Luo
机构：Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center · ORCID：0000-0003-3606-827X
发表论文 318 篇 · 总被引 3035 次 · h-index 23
代表论文
- A phase 1/2, open-label study of oral S241656 (BDTX-4933) as monotherapy and in combination with other anti-cancer therapies in patients with KRAS, BRAF and other selected RAS/MAPK mutation positive malignancies. (2026 · Journal of Clinical Oncology · 被引 1)
- BET bromodomain 2 inhibition facilitates SPOP-mediated degradation of chromatin-associated BRD4/BRD4-NUT, a therapeutic vulnerability in NUT carcinoma (2026 · bioRxiv (Cold Spring Harbor Laboratory))
- Presenting Features and Outcomes to Standard Systemic Therapies in Patients with MTAP -Deleted Advanced Non–Small Cell Lung Cancer (2026 · Clinical Cancer Research)
- PP01.43: Machine Learning-Guided Treatment Selection for KRAS-Altered and Wild-Type Metastatic Non-Squamous Non-Small Cell Lung Cancer (2026 · Journal of Thoracic Oncology)
- PP01.28: Outcomes to Systemic Standard-of-Care in Patients with MTAP-deleted Advanced NSCLC (2026 · Journal of Thoracic Oncology)
- TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors (2026 · Journal of Thoracic Oncology)